Finance

Lists
Why is 1541 up 2,58%?
Dive Deeper
1541:HKG
ImmuneOnco Biopharmaceuticals(Shngh) Inc
2,98 HKD
+2,58%
(+0,075) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1541...
Open
2,98 HKD
High
3,07 HKD
Low
2,92 HKD
Mkt. cap
1,28 млд
Avg. vol.
385,40 миң
Volume
273,40 миң
52-wk high
11,90 HKD
52-wk low
2,80 HKD
EPS
-0,63 HKD
No. of employees
197
Open
2,98 HKD
High
3,07 HKD
Low
2,92 HKD
Mkt. cap
1,28 млд
Avg. vol.
385,40 миң
Volume
273,40 миң
52-wk high
11,90 HKD
52-wk low
2,80 HKD
EPS
-0,63 HKD
No. of employees
197
News stories
From web sources and news partners
About ImmuneOnco Biopharmaceuticals(Shngh) Inc
CEO-
Employees197
Founded2015
Headquarters-
Sector-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
55,14 млн
55,14 млн
18,62 млн
18,62 млн
Cost of goods sold
555,00 миң
555,00 миң
-
-
Cost of revenue
555,00 миң
555,00 миң
-
-
Research and development expenses
77,12 млн
77,12 млн
77,39 млн
77,39 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,34 млн
13,34 млн
11,60 млн
11,60 млн
Operating expense
90,46 млн
90,46 млн
88,99 млн
88,99 млн
Total operating expenses
91,01 млн
91,01 млн
88,99 млн
88,99 млн
Operating income
-35,87 млн
-35,87 млн
-70,36 млн
-70,36 млн
Other non operating income
4,90 млн
4,90 млн
-6,50 миң
-6,50 миң
EBT including unusual items
-33,27 млн
-33,27 млн
-82,74 млн
-82,74 млн
EBT excluding unusual items
-33,47 млн
-33,47 млн
-77,67 млн
-77,67 млн
Income tax expense
14,50 миң
14,50 миң
11,50 миң
11,50 миң
Effective tax rate
-0,04%
-0,04%
-0,01%
-0,01%
Other operating expenses
-
-
-
-
Net income
-33,00 млн
-33,00 млн
-82,09 млн
-82,09 млн
Net profit margin
-59,84%
-59,84%
-440,81%
-440,81%
Earnings per share
-
-
-
-
Interest and investment income
1,57 млн
1,57 млн
2,28 млн
2,28 млн
Interest expense
-1,43 млн
-1,43 млн
-2,12 млн
-2,12 млн
Net interest expenses
136,00 миң
136,00 миң
165,50 миң
165,50 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,84 млн
-33,84 млн
-68,41 млн
-68,41 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору